Results From a Phase 3 Study Show Iroko Pharmaceuticals’s Investigational Submicron Indomethacin Provided Effective Pain Relief at Lower Doses
PHILADELPHIA--(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC today announced that the Phase 3 study evaluating the company’s investigational, lower dose submicron indomethacin in post-surgical acute pain met its primary endpoint of demonstrating significant pain relief compared with placebo. Full results from the study will be presented at a future medical meeting.